<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Alterity Therapeutics Ltd — News on 6ix</title>
    <link>https://6ix.com/company/alterity-therapeutics-ltd</link>
    <description>Latest news and press releases for Alterity Therapeutics Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 11:25:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/alterity-therapeutics-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836629d78dffbe2df15c6ff.webp</url>
      <title>Alterity Therapeutics Ltd</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd</link>
    </image>
    <item>
      <title>Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-receives-positive-fda-feedback-following-second-type-c-meeting-on-ath434-phase-3-program-in-multiple-system-atrophy</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-receives-positive-fda-feedback-following-second-type-c-meeting-on-ath434-phase-3-program-in-multiple-system-atrophy</guid>
      <pubDate>Mon, 27 Apr 2026 11:25:00 GMT</pubDate>
      <description>– Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale-up progressing in parallel – – End-of-Phase 2 meeting with FDA remains on track for mid-2026 – MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing d</description>
    </item>
    <item>
      <title>Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-presents-new-analysis-of-ath434-phase-2-trial-data-in-late-breaking-science-session-of-the-american-academy-of-neurology</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-presents-new-analysis-of-ath434-phase-2-trial-data-in-late-breaking-science-session-of-the-american-academy-of-neurology</guid>
      <pubDate>Wed, 22 Apr 2026 11:25:00 GMT</pubDate>
      <description>- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previously reported activity on modified UMSARS Part I - - Presentation reinforces ATH434&apos;s clinical profile ahead of Phase 3 engagement with regulators - MELBOURNE, Australia and SAN FRANCISCO, April 22, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),</description>
    </item>
    <item>
      <title>Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-appoints-highly-experienced-biotech-executive-ann-cunningham-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-appoints-highly-experienced-biotech-executive-ann-cunningham-to-its-board-of-directors</guid>
      <pubDate>Fri, 17 Apr 2026 11:25:00 GMT</pubDate>
      <description>MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Ms Ann Cunningham to its Board of Directors as an independent Non-Executive Director, effective 17th April 2026. Ms Cunningham’s appointment further strengthens Alterity’s Board composition, adding signi</description>
    </item>
    <item>
      <title>Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-announces-late-breaker-oral-presentation-at-the-american-academy-of-neurology-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-announces-late-breaker-oral-presentation-at-the-american-academy-of-neurology-annual-meeting</guid>
      <pubDate>Thu, 16 Apr 2026 11:25:00 GMT</pubDate>
      <description>MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will deliver an oral presentation during a Late Breaking Session at the American Acad</description>
    </item>
    <item>
      <title>Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-to-host-virtual-kol-event-to-share-new-insights-on-ath434-for-the-treatment-of-multiple-system-atrophy</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-to-host-virtual-kol-event-to-share-new-insights-on-ath434-for-the-treatment-of-multiple-system-atrophy</guid>
      <pubDate>Wed, 15 Apr 2026 11:25:00 GMT</pubDate>
      <description>MELBOURNE, Australia and SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event featuring Roy Freeman, MD (Harvard Medical School, Beth Israel Deaconess Medical Center) and Daniel Claassen, MD, MS (Vanderbilt University Medical Center), alongs</description>
    </item>
    <item>
      <title>Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-receives-positive-fda-feedback-following-type-c-meeting-on-ath434-phase-3-program</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-receives-positive-fda-feedback-following-type-c-meeting-on-ath434-phase-3-program</guid>
      <pubDate>Mon, 30 Mar 2026 11:25:00 GMT</pubDate>
      <description>Alignment reached on key elements of ATH434 Phase 3 development programMELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3</description>
    </item>
    <item>
      <title>Alterity Receives Positive FDA Feedback From Type C Meeting</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-receives-positive-fda-feedback-from-type-c-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-receives-positive-fda-feedback-from-type-c-meeting</guid>
      <pubDate>Mon, 30 Mar 2026 03:18:03 GMT</pubDate>
      <description>Alterity Receives Positive FDA Feedback From Type C Meeting</description>
    </item>
    <item>
      <title>Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-to-participate-in-the-bell-potter-healthcare-horizons-summit</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-to-participate-in-the-bell-potter-healthcare-horizons-summit</guid>
      <pubDate>Mon, 09 Mar 2026 11:25:00 GMT</pubDate>
      <description>MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia. At the conference, Dr. Stamler will partic</description>
    </item>
    <item>
      <title>Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-appoints-daniel-o-claassen-md-ms-as-chief-medical-advisor</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-appoints-daniel-o-claassen-md-ms-as-chief-medical-advisor</guid>
      <pubDate>Wed, 04 Mar 2026 12:25:00 GMT</pubDate>
      <description>– Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise –MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured profes</description>
    </item>
    <item>
      <title>Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-recognizes-multiple-system-atrophy-msa-awareness-month-in-march-and-the-urgent-need-for-disease-modifying-treatments</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-recognizes-multiple-system-atrophy-msa-awareness-month-in-march-and-the-urgent-need-for-disease-modifying-treatments</guid>
      <pubDate>Mon, 02 Mar 2026 12:25:00 GMT</pubDate>
      <description>– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN FRANCISCO, March 02, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, recognizes Multiple System Atrophy (MSA) Awareness Month this March</description>
    </item>
    <item>
      <title>Half Yearly Report and Accounts</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/half-yearly-report-and-accounts-235</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/half-yearly-report-and-accounts-235</guid>
      <pubDate>Thu, 26 Feb 2026 03:40:12 GMT</pubDate>
      <description>Half Yearly Report and Accounts</description>
    </item>
    <item>
      <title>Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report &amp; Corporate Update</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-appendix-4c-q2-122500527</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-appendix-4c-q2-122500527</guid>
      <pubDate>Fri, 30 Jan 2026 12:25:00 GMT</pubDate>
      <description>− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers</description>
    </item>
    <item>
      <title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-58</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-58</guid>
      <pubDate>Fri, 30 Jan 2026 04:25:10 GMT</pubDate>
      <description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
    </item>
    <item>
      <title>Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-issues-shareholder-letter-122500242</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-issues-shareholder-letter-122500242</guid>
      <pubDate>Wed, 21 Jan 2026 12:25:00 GMT</pubDate>
      <description>MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders. Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable u</description>
    </item>
    <item>
      <title>Alterity Board Changes</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-board-changes</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-board-changes</guid>
      <pubDate>Fri, 21 Nov 2025 03:20:49 GMT</pubDate>
      <description>Alterity Board Changes</description>
    </item>
    <item>
      <title>Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-present-bell-potter-122500759</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-present-bell-potter-122500759</guid>
      <pubDate>Wed, 12 Nov 2025 12:25:00 GMT</pubDate>
      <description>MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia’s best healthcare companies. Presentation details</description>
    </item>
    <item>
      <title>Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-presents-promising-impact-122500522</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-presents-promising-impact-122500522</guid>
      <pubDate>Mon, 10 Nov 2025 12:25:00 GMT</pubDate>
      <description>– Data highlights symptom stability and enhanced efficacy signals in higher dose group – – Analysis offers valuable insights to guide ongoing development and planning of Phase 3 – MELBOURNE, Australia and SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that analyses on the baseline characteristi</description>
    </item>
    <item>
      <title>Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-appendix-4c-q1-112500296</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-appendix-4c-q1-112500296</guid>
      <pubDate>Fri, 31 Oct 2025 11:25:00 GMT</pubDate>
      <description>Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced MSA as observed in earlier stage patients in double-blind studyIndependent commercial assessment indicates USD $2.4 billion dollar potential worldwide peak sales opportunity in MSA for ATH434Cash balance on 30 September 2025 of A$54.56M MELBOURNE, Australia and SAN FRANCISCO, Oct. 31, 2025 (GLOBE NE</description>
    </item>
    <item>
      <title>Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-presents-positive-data-112500032</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-presents-positive-data-112500032</guid>
      <pubDate>Thu, 09 Oct 2025 11:25:00 GMT</pubDate>
      <description>– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neuroimaging and biomarker analysis advance understanding of MSA diagnosis – MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neu</description>
    </item>
    <item>
      <title>Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders</title>
      <link>https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-deliver-multiple-presentations-113500071</link>
      <guid isPermaLink="true">https://6ix.com/company/alterity-therapeutics-ltd/news/alterity-therapeutics-deliver-multiple-presentations-113500071</guid>
      <pubDate>Thu, 02 Oct 2025 11:35:00 GMT</pubDate>
      <description>– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations – MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (</description>
    </item>
  </channel>
</rss>